ELIZABETH WILBANKS: Open Payments
NPI 1174870802 · CORINTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 36 payments from 9 companies in 2025. Trend: 2023 $472 · 2024 $503 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $174 |
| Amgen Inc. | 12 | $157 |
| Novo Nordisk Inc | 6 | $91 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| GlaxoSmithKline, LLC. | 2 | $28 |
| Boston Scientific Corporation | 1 | $27 |
| Dexcom, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $20 |
Products named: Veozah, EVENITY, Auvelity, Wegovy, OTEZLA, Rybelsus, TRELEGY ELLIPTA, ENROUTE Transcarotid Neuroprotection System.
Industry payments across MS — which companies pay providers there.
